Repligen Corp. 10-Q Summary: Quarter Ended June 30, 2007
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2007. Repligen Corporation is a biopharmaceutical company focused on developing novel therapeutics for central nervous system diseases. Its commercial revenue is derived primarily from the sale of Protein A products for monoclonal antibody purification and SecreFlo for pancreatic disorder assessment. The company operates as a single segment.
Key Financial Metrics
| Metric | Q2 2007 | Q2 2006 |
|---|---|---|
| Total Revenue | $5,978,818 | $3,628,168 |
| Net Income | $239,978 | $100,734 |
| EPS (Basic/Diluted) | $0.01 | $0.00 |
| Operating Cash Flow | ($754,083) | ($304,510) |
| Cash & Marketable Securities | $20,138,048 | N/A |
| Total Assets | $29,910,690 | N/A |
| Total Liabilities | $3,525,130 | N/A |
| Stockholders' Equity | $26,385,560 | N/A |
Note: Gross margin for the quarter was approximately 71% ($4.26M gross profit / $5.98M revenue).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 65% year-over-year, driven by a 78% increase in Protein A sales volume and favorable product mix pricing. SecreFlo revenue increased 18%.
- Expense Increases: Total operating expenses rose 60% to $5.99M.
- R&D: Increased 76% to $2.14M, largely due to a $600,000 milestone payment (cash and stock) for a license agreement with The Scripps Research Institute and increased clinical trial costs.
- SG&A: Increased 39% to $2.14M, primarily due to a $595,000 increase in litigation expenses related to patent infringement lawsuits against Bristol-Myers Squibb and ImClone.
- Profitability: Despite higher expenses, the company reported a net income of $240,000 compared to $101,000 in the prior year, aided by increased investment income ($257,000 vs. $225,000).
- Cash Flow: Operating cash flow turned negative at ($754,000), compared to ($305,000) in the prior year, driven by a significant increase in accounts receivable ($1.55M increase) and inventory build-up.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash and investment balances (~$21.8M) are sufficient to meet needs for at least the next 24 months. Working capital decreased slightly to $21.55M.
- Revenue Outlook: SecreFlo revenues are expected to decline by one-third in fiscal 2008 as the company reduces sales efforts and depletes inventory from a sole supplier. Research and license revenues are also expected to decline moderately.
- Strategic Initiatives: The company entered an exclusive license with The Scripps Research Institute for compounds treating Friedreich's Ataxia. It continues to pursue patent infringement litigation against ImClone (trial set for Sept 2007) and Bristol-Myers Squibb (trial set for April 2008).
- Risks: Key risks include dependence on a few major customers (two customers accounted for ~81% of product revenue), the outcome of ongoing litigation, and the uncertainty of clinical trial results for therapeutic candidates.
Investor Verification Checklist
- Verify the status and potential financial impact of the patent infringement lawsuits against ImClone and Bristol-Myers Squibb.
- Monitor the decline in SecreFlo revenue and the timeline for inventory depletion.
- Assess the progress and milestone triggers associated with the new Scripps Research Institute license agreement.
- Review the concentration risk regarding the top two customers who generated 81% of product revenue.
- Confirm the company's ability to sustain R&D spending given the cash burn from operating activities.